Erasca, Inc. (ERAS)
- GlobeNewswire
Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting
Oral presentation will feature updated HERKULES-3 results for ERK1/2 inhibitor ERAS-007 in combination with encorafenib and cetuximab in BRAFm colorectal cancer Poster presentations will feature SEACRAFT-1 Phase 1 trial design for naporafenib plus trametinib in RAS Q61X mutations, and preliminary FLAGSHP-1 Phase 1 results for ERAS-601 and cetuximab in chordoma SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused
- Zacks
Erasca (ERAS) Upgraded to Strong Buy: What Does It Mean for the Stock?
Erasca (ERAS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Simply Wall St.
Institutional investors may adopt severe steps after Erasca, Inc.'s (NASDAQ:ERAS) latest 11% drop adds to a year losses
Key Insights Significantly high institutional ownership implies Erasca's stock price is sensitive to their trading...
